**Summary**
Aptamer Group PLC, a developer of next-generation synthetic binders for the life sciences industry, announced significant commercial progress on January 29, 2026. The company secured **£190,000 in new fee-for-service contracts and extensions**, including repeat business with top-tier pharmaceutical partners, bringing its FY26 fee-for-service order book to over **£2.1 million**. Additionally, Aptamer received its **first cash licensing receipts of £80,000** from a hot-start PCR Optimer® license, marking the transition to high-margin, recurring revenues.
Key highlights include
**Repeat contracts** with a top-10 global pharmaceutical company and other leading industry players, demonstrating sustained adoption of the Optimer® platform.
A new Optimer® development program for novel fertility solutions, with Aptamer retaining full intellectual property rights for potential downstream licensing.
The first cash licensing receipts are expected to contribute **15% of annual overhead** over the next three years, showcasing operational leverage.
A strong financial position with funding runway through **June 2027**, supporting continued revenue growth and progress toward cash-flow break-even.
CEO Dr. Arron Tolley emphasized the company’s progress in building a higher-quality, recurring revenue business, with confidence in delivering year-on-year growth and enhancing shareholder value.